Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01511562 · OUTCOME

Event Free Survival

Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma · Source last updated 2026-01-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants w/out event
Interval / dispersion
95% Confidence Interval
Time frame
2 years

What was measured

To compare the two-year event-free survival (EFS) of patients treated with consolidation HDT/ASCT versus those treated with consolidation chemotherapy consisting of etoposide and cytarabine. EFS event = same definition as PFS with non-protocol treatment also considered an event

Groups in this outcome

Arm I

Patients undergo induction therapy for five cycles as defined in the protocol. Patients undergo stem cell transplant. \> \> carmustine: Given IV \> \> thiotepa: Given IV \> \> stem cell transplant \> \> G-CSF

Arm II

Patients undergo induction therapy for five cycles as defined in the protocol. Patients undergo consolidation chemotherapy. \> \> cytarabine: Given IV \> \> etoposide: Given IV \> \> G-CSF

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm I54
Arm II54

Reported measurements

Source class 1
Values in percentage of participants w/out event · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Arm I65.7Not reported51.276.9Not reported
Arm II48.5Not reported34.261.4Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        51.2
        upper Limit
        76.9
        value
        65.7
      2. group Id
        OG001
        lower Limit
        34.2
        upper Limit
        61.4
        value
        48.5
denoms
  1. counts
    1. group Id
      OG000
      value
      54
    2. group Id
      OG001
      value
      54
    units
    Participants
description
To compare the two-year event-free survival (EFS) of patients treated with consolidation HDT/ASCT versus those treated with consolidation chemotherapy consisting of etoposide and cytarabine. EFS event = same definition as PFS with non-protocol treatment also considered an event
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients undergo induction therapy for five cycles as defined in the protocol. Patients undergo stem cell transplant. \> \> carmustine: Given IV \> \> thiotepa: Given IV \> \> stem cell transplant \> \> G-CSF
    id
    OG000
    title
    Arm I
  2. description
    Patients undergo induction therapy for five cycles as defined in the protocol. Patients undergo consolidation chemotherapy. \> \> cytarabine: Given IV \> \> etoposide: Given IV \> \> G-CSF
    id
    OG001
    title
    Arm II
param Type
NUMBER
reporting Status
POSTED
time Frame
2 years
title
Event Free Survival
type
SECONDARY
unit Of Measure
percentage of participants w/out event

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice